{"disease":{"id":"tyrosine-kinase-inhibitor","name":"tyrosine kinase inhibitor"},"drugs":{"marketed":[{"drug_id":"gm-csf","indication_name":"Chronic Myeloid Leukemia (CML) in adult patients with Philadelphia chromosome-positive (Ph+) disease who are refractory or resistant to at least one prior tyrosine kinase inhibitor (TKI) therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Chronic Myeloid Leukemia (CML) in adult patients with Philadelphia chromosome-positive (Ph+) disease who are refractory or resistant to at least one prior tyrosine kinase inhibitor (TKI) therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05221372","title":"ProSpecTive sAmpling in dRiver muTation Pulmonary Oncology Patients on Tyrosine Kinase Inhibitors (START-TKI)","phase":"","overall_status":"RECRUITING","enrollment_count":1300,"lead_sponsor_name":"Erasmus Medical Center","has_results":false},{"nct_id":"NCT04832672","title":"Sequence of Radiation and Targeted Therapy in Brain Metastases","phase":"","overall_status":"COMPLETED","enrollment_count":570,"lead_sponsor_name":"Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT07418138","title":"Effect of Pre-Transplant Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma Patients With Liver Transplantation","phase":"","overall_status":"COMPLETED","enrollment_count":484,"lead_sponsor_name":"Hu Liangshuo","has_results":false},{"nct_id":"NCT07449065","title":"CECT Features of MVI Predict Response to TACE Plus TKI in Intermediate-stage HCC","phase":"","overall_status":"COMPLETED","enrollment_count":324,"lead_sponsor_name":"First Affiliated Hospital, Sun Yat-Sen University","has_results":false},{"nct_id":"NCT06662877","title":"Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment","phase":"PHASE2, PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":206,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT04862780","title":"(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":177,"lead_sponsor_name":"Blueprint Medicines Corporation","has_results":false},{"nct_id":"NCT05621148","title":"REfractorinesS to Ibrutinib BTKi and Systemic Targeted Therapy","phase":"","overall_status":"COMPLETED","enrollment_count":152,"lead_sponsor_name":"French Innovative Leukemia Organisation","has_results":false},{"nct_id":"NCT04997850","title":"The Safety and Efficacy of Transarterial Chemoembolization (TACE) + Lenvatinib + Programmed Cell Death Protein 1 (PD-1) Antibody of Advanced Unresectable Hepatocellular Carcinoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":142,"lead_sponsor_name":"Xinrui Zhu，MD","has_results":false},{"nct_id":"NCT05753384","title":"Discontinuation of TyrosIne Kinase Inhibitors (TKI) in Chronic Myeloid Leukemia (CML) and Impact on the Immune System","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":140,"lead_sponsor_name":"Poitiers University Hospital","has_results":false},{"nct_id":"NCT07267247","title":"Cancer Therapy-Related Cardiac Dysfunction Associated With EGFR-TKIs in Advanced EGFR-mutant Non-small Cell Lung Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Taichung Veterans General Hospital","has_results":false},{"nct_id":"NCT06632106","title":"HAIC in Combination with Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Advanced HCC","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":97,"lead_sponsor_name":"First Hospital of China Medical University","has_results":false},{"nct_id":"NCT03952312","title":"Oncotool for Cancer Medications","phase":"NA","overall_status":"COMPLETED","enrollment_count":83,"lead_sponsor_name":"Northwestern University","has_results":false},{"nct_id":"NCT03257124","title":"Study of AZD9291 in NSCLC Patients Harboring T790M Mutation Who Failed EGFR TKI and With Brain and/or LMS","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":80,"lead_sponsor_name":"Samsung Medical Center","has_results":false},{"nct_id":"NCT05824312","title":"HRQOL in Locally Advanced Thyroid Carcinoma","phase":"","overall_status":"UNKNOWN","enrollment_count":80,"lead_sponsor_name":"Fujian Cancer Hospital","has_results":false},{"nct_id":"NCT06755684","title":"Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Peng Zhang","has_results":false},{"nct_id":"NCT04807166","title":"Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":56,"lead_sponsor_name":"Wenjun Cheng","has_results":false},{"nct_id":"NCT06658925","title":"Olverembatinib as Maintenance Therapy or Preemptive Therapy After Allo-HSCT in Ph+ALL","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":50,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT06167460","title":"Analysis of Circulating Tumor DNA Dynamics to Predict and Monitor Response to TKI in Patients With Advanced NSCLC.","phase":"","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Gene Solutions","has_results":false},{"nct_id":"NCT03996096","title":"Tyrosine Kinase Inhibitor Withdrawal Syndrome in CML Patients: Observatory Trial Studying the Biological Factors.","phase":"","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"University Hospital, Caen","has_results":false},{"nct_id":"NCT05311943","title":"Treatment With Olverembatinib in CML-CP Patients Who Failed to at Least Two Previously Administered Second-generation TKIs.","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Shenzhen Second People's Hospital","has_results":false},{"nct_id":"NCT07092202","title":"Firmonertinib Combined With Intrathecal Injection for the Treatment of EGFR Mutant NSCLC With Leptomeningeal Metastases","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","has_results":false},{"nct_id":"NCT05263947","title":"Bevacizumab Combined With Double Doses of Icotinib in Advanced NSCLC Patients With EGFR L858R Mutation","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":35,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false},{"nct_id":"NCT05153408","title":"(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":20,"lead_sponsor_name":"Blueprint Medicines Corporation","has_results":false},{"nct_id":"NCT01914484","title":"Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":4,"lead_sponsor_name":"University Health Network, Toronto","has_results":false}],"total":24},"guidelines":[],"source":"Drug Landscape verified database"}